<ol class="cite-this-references"><li id="reference-A177871">Lucas S: The Pharmacology of Indomethacin. Headache. 2016 Feb;56(2):436-46. doi: 10.1111/head.12769. Epub 2016 Feb 11. [<a href="/articles/A177871" target="_blank">Article</a>] </li><li id="reference-A177874">Helleberg L: Clinical Pharmacokinetics of indomethacin. Clin Pharmacokinet. 1981 Jul-Aug;6(4):245-58. doi: 10.2165/00003088-198106040-00001. [<a href="/articles/A177874" target="_blank">Article</a>] </li><li id="reference-A177877">Nalamachu S, Wortmann R: Role of indomethacin in acute pain and inflammation management: a review of the literature. Postgrad Med. 2014 Jul;126(4):92-7. doi: 10.3810/pgm.2014.07.2787. [<a href="/articles/A177877" target="_blank">Article</a>] </li><li id="reference-A177880">Pacifici GM: Clinical pharmacology of indomethacin in preterm infants: implications in patent ductus arteriosus closure. Paediatr Drugs. 2013 Oct;15(5):363-76. doi: 10.1007/s40272-013-0031-7. [<a href="/articles/A177880" target="_blank">Article</a>] </li><li id="reference-A177901">Jensen KM, Grenabo L: Bioavailability of indomethacin after intramuscular injection and rectal administration of solution and suppositories. Acta Pharmacol Toxicol (Copenh). 1985 Nov;57(5):322-7. [<a href="/articles/A177901" target="_blank">Article</a>] </li><li id="reference-A177949">Weber M, Kodjikian L, Kruse FE, Zagorski Z, Allaire CM: Efficacy and safety of indomethacin 0.1% eye drops compared with ketorolac 0.5% eye drops in the management of ocular inflammation after cataract surgery. Acta Ophthalmol. 2013 Feb;91(1):e15-21. doi: 10.1111/j.1755-3768.2012.02520.x. Epub 2012 Sep 12. [<a href="/articles/A177949" target="_blank">Article</a>] </li><li id="reference-A177964">Alvan G, Orme M, Bertilsson L, Ekstrand R, Palmer L: Pharmacokinetics of indomethacin. Clin Pharmacol Ther. 1975 Sep;18(3):364-73. [<a href="/articles/A177964" target="_blank">Article</a>] </li><li id="reference-A176366">Ricciotti E, FitzGerald GA: Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011 May;31(5):986-1000. doi: 10.1161/ATVBAHA.110.207449. [<a href="/articles/A176366" target="_blank">Article</a>] </li><li id="reference-A177979">Rouzer CA, Marnett LJ: Cyclooxygenases: structural and functional insights. J Lipid Res. 2009 Apr;50 Suppl:S29-34. doi: 10.1194/jlr.R800042-JLR200. Epub 2008 Oct 23. [<a href="/articles/A177979" target="_blank">Article</a>] </li><li id="reference-A486">HART FD, BOARDMAN PL: INDOMETHACIN: A NEW NON-STEROID ANTI-INFLAMMATORY AGENT. Br Med J. 1963 Oct 19;2(5363):965-70. [<a href="/articles/A486" target="_blank">Article</a>] </li><li id="reference-A234429">Brunelli C, Amici C, Angelini M, Fracassi C, Belardo G, Santoro MG: The non-steroidal anti-inflammatory drug indomethacin activates the eIF2alpha kinase PKR, causing a translational block in human colorectal cancer cells. Biochem J. 2012 Apr 15;443(2):379-86. doi: 10.1042/BJ20111236. [<a href="/articles/A234429" target="_blank">Article</a>] </li><li id="reference-A234434">Amici C, La Frazia S, Brunelli C, Balsamo M, Angelini M, Santoro MG: Inhibition of viral protein translation by indomethacin in vesicular stomatitis virus infection: role of eIF2alpha kinase PKR. Cell Microbiol. 2015 Sep;17(9):1391-404. doi: 10.1111/cmi.12446. Epub 2015 May 13. [<a href="/articles/A234434" target="_blank">Article</a>] </li><li id="reference-L6778">Indomethacin Capsules (25 mg) - FDA Label [<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/016059s100lbl.pdf" target="_blank">Link</a>] </li><li id="reference-L10553">Indocin I.V. (indomethacin for injection) - FDA Label [<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018878s027lbl.pdf" target="_blank">Link</a>] </li><li id="reference-L13269">FDA Approved Drug Products: INDOCIN (indomethacin) Suppositories, for rectal use [<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017814s041s042lbl.pdf" target="_blank">Link</a>] </li></ol>